MedPharm, a global provider of contract topical and transdermal formulation development and manufacturing services, is pleased to announce that it will support Swiss Biotech company, Mosanna Therapeutics, in the development of a nasal spray (MOS-118) aimed at treating Metabolic Obstructive Sleep Apnea (MOSA).

The collaboration will focus on advancing MOS-118 into clinical development. Mosanna is developing MOS-118 to prevent the airway from collapsing during sleep in a disease that affects up to 1 billion globally. The repeated partial or complete obstruction of the upper airway during sleep is associated with adverse metabolic and cardiovascular events and can severely impact the quality of life for patients.

MedPharm, a global Contract Development and Manufacturing Organization that specializes in topical and transdermal drug product development, recently completed a Medicines and Healthcare products Regulatory Agency (MHRA) GMP audit of its Guildford locations. We are happy to announce there were no critical or major findings from the audit.

These evaluations of MedPharm’s systems and compliance with regulatory standards are further confirmation of MedPharm’s commitment to providing the gold standard in topical development and manufacturing services.

To learn more about MedPharm’s capabilities, view our virtual facility tours or contact our team today.